Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the must-buy small-cap stocks to invest in. On August 18, the company confirmed it will end its strategic collaboration and license agreement with Genentech effective February 9, 2026. The strategic collaboration focuses on the research and development of cancer cell therapy products.

The termination of the agreement will relieve Adaptive Biotechnologies of exclusive obligations related to oncology cell therapies. The company is to realize $33.7 million in non-cash revenue as a result of the termination agreement in the second half of the year.

Following the termination, Adaptive Biotechnologies is to continue working on its Immune Medicine programs. Its financial programs will also remain focused on developing digital TCR-antigen prediction models. It also plans to advance the development of its lead T-cell depletion program.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage biotechnology company focused on leveraging the adaptive immune system to diagnose and treat diseases. It leverages its proprietary immune medicine platform to decode and translate the genetic information of the adaptive immune system, enabling the development of clinical products for various diseases.

While we acknowledge the potential of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.